- Home
- GNPX vs GXAI Comparison
GNPX vs GXAI Comparison
Compare GNPX & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- GXAI
- Stock Information
- Founded
- GNPX 2009
- GXAI 2021
- Country
- GNPX United States
- GXAI United States
- Employees
- GNPX N/A
- GXAI N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- GXAI
- Sector
- GNPX Health Care
- GXAI
- Exchange
- GNPX Nasdaq
- GXAI Nasdaq
- Market Cap
- GNPX 10.8M
- GXAI 13.0M
- IPO Year
- GNPX 2018
- GXAI 2023
- Fundamental
- Price
- GNPX $6.64
- GXAI $1.64
- Analyst Decision
- GNPX
- GXAI
- Analyst Count
- GNPX 0
- GXAI 0
- Target Price
- GNPX N/A
- GXAI N/A
- AVG Volume (30 Days)
- GNPX 1.7M
- GXAI 364.2K
- Earning Date
- GNPX 11-14-2025
- GXAI 11-13-2025
- Dividend Yield
- GNPX N/A
- GXAI N/A
- EPS Growth
- GNPX N/A
- GXAI N/A
- EPS
- GNPX N/A
- GXAI N/A
- Revenue
- GNPX N/A
- GXAI $198,711.00
- Revenue This Year
- GNPX N/A
- GXAI N/A
- Revenue Next Year
- GNPX N/A
- GXAI N/A
- P/E Ratio
- GNPX N/A
- GXAI N/A
- Revenue Growth
- GNPX N/A
- GXAI 72158.55
- 52 Week Low
- GNPX $6.51
- GXAI $1.00
- 52 Week High
- GNPX $140.00
- GXAI $7.50
- Technical
- Relative Strength Index (RSI)
- GNPX 63.07
- GXAI 45.68
- Support Level
- GNPX $7.71
- GXAI $1.52
- Resistance Level
- GNPX $9.89
- GXAI $1.81
- Average True Range (ATR)
- GNPX 1.15
- GXAI 0.16
- MACD
- GNPX 0.53
- GXAI -0.03
- Stochastic Oscillator
- GNPX 50.54
- GXAI 18.19
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.